Provided by Tiger Trade Technology Pte. Ltd.

Corvus Pharmaceuticals

13.94
-0.2250-1.59%
Volume:221.14K
Turnover:3.07M
Market Cap:1.17B
PE:-22.29
High:14.16
Open:14.09
Low:13.71
Close:14.16
52wk High:26.95
52wk Low:5.58
Shares:83.77M
Float Shares:74.12M
Volume Ratio:0.53
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6252
EPS(LYR):-0.5320
ROE:-35.43%
ROA:-21.66%
PB:5.18
PE(LYR):-26.19

Loading ...

Press Release: Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Dow Jones
·
Jun 09

Corvus Pharma posts corporate deck highlighting soquelitinib ITK inhibitor program across immune diseases and T‑cell lymphoma

Reuters
·
Jun 04

Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness

Simply Wall St.
·
Jun 02

Top Executive Makes Bold Insider Move on Corvus Pharmaceuticals Stock

TIPRANKS
·
May 21

Corvus CEO Richard Miller reports trust buy of USD 83,112 common shares

Reuters
·
May 21

Corvus Pharmaceuticals presents at Jefferies Global Healthcare Conference

Reuters
·
May 21

Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk

Dow Jones
·
May 14

Goldman Sachs Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 12

Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS

Simply Wall St.
·
May 12

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 11

Stock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses

Stock Track
·
May 08

Corvus Q1 FY26 results: net loss widens to $13.7 million; R&D expense rises to $11.2 million

Reuters
·
May 08

Corvus Pharma Q1 EPS $(0.15), Inline

Benzinga Earnings
·
May 08

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 08

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board

Simply Wall St.
·
May 03

Earning Preview: Corvus Pharmaceuticals revenue is expected to be flat, and institutional views are broadly bullish

Earnings Agent
·
May 01

Corvus Pharmaceuticals director Andrew C. Chan files initial beneficial ownership statement

Reuters
·
Apr 28

Corvus Pharmaceuticals announces upcoming annual shareholder meeting

Reuters
·
Apr 25

Press Release: Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

Dow Jones
·
Apr 23

Corvus publishes update to financial calendar

Reuters
·
Apr 21